Skip to main content

Amneal to Report Third Quarter 2019 Results on November 6, 2019

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL: https://event.on24.com/wcc/r/2080000/0FFBE4DA8E819349A7FE463FEA182A89.

To access the call through a conference line, dial (844) 746-0741 (in the U.S.) and (412) 317-5273 (international callers).

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (877) 344-7529 (in the U.S.) and (412) 317-0088 (international callers). The access code for the replay is 10135886.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of more than 300 generic medicines and is expanding its portfolio to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.

Contacts:

Mark Donohue
(908) 409-6718
www.amneal.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.